Patents Issued in March 20, 2018
  • Patent number: 9920100
    Abstract: The present invention provides isolated peptides and nucleic acids encoding the isolated peptides that can modify a subject's immune response to tropomyosin. The isolated peptides correspond to peptide epitope mimics that are based on an invertebrate tropomyosin allergen, e.g., the shrimp tropomyosin Met e 1. Also provided are compositions and methods of use thereof to reduce, minimize or eliminate an allergic response to arthropods and/or shellfish.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 20, 2018
    Assignees: The Chinese University of Hong Kong, The Regents of the University of California
    Inventors: Patrick Leung, Ka Hou Chu, Yee Yan Wai, Yat Hin Nicki Leung
  • Patent number: 9920101
    Abstract: The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: March 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Horst Rose, Dania Birte Reiche, Harald Tammen
  • Patent number: 9920102
    Abstract: Fluorescent and non-fluorescent fusion tags derived from green fluorescent protein (GFP). The fusion tags harbor substitutions with respect to GFP that increase expression of target proteins to which the fusion tags are fused; increase solubility; prevent dimerization and oligomerization, particularly in oxidizing environments such as the endoplasmic reticulum (ER); and, in some cases, enhance fluorescence of the fusion tag itself. The substitutions include various combinations of substitutions at select cysteine residues in GFP, substitutions in or near the GFP chromophore, and/or other substitutions. The fusion tags can be used for increasing expression of target proteins for mass production thereof or as a fluorescent tag.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: March 20, 2018
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Erik Lee Snapp, Lindsey M. Costantini
  • Patent number: 9920103
    Abstract: The invention relates to obtaining a preparation of recombinant human PLTP from the milk of a transgenic animal containing in its genome one or more copies of a transgene comprising a polynucleotide coding for human PTLP, placed under transcriptional control of a promoter permitting its specific expression in the cells of the mammary glands of said animal. The recombinant human PLTP preparation obtained can be used in the prevention or treatment of septic shock.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: March 20, 2018
    Assignees: BIOPROTEIN TECHNOLOGIES SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Pierre-Jean Ripoll, Laurent Lagrost
  • Patent number: 9920104
    Abstract: The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: March 20, 2018
    Assignee: UT-Battelle, LLC
    Inventor: Cymbeline T. Culiat
  • Patent number: 9920105
    Abstract: A fusion polypeptide, including a first polypeptide fragment including 5 to 30 amino acids, the first polypetide fragment is fused between a first amino acid and a fifth amino acid of a fourth loop of a human-derived ferritin monomer.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 20, 2018
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Eunsung Jun, Jaeog Jeon, Soyoun Kim, In-Seop So, In-San Kim, Sun-Ji Kim
  • Patent number: 9920106
    Abstract: Novel GLP-1 compounds and their therapeutic use.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: March 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Jesper Lau, Kjeld Madsen, Thomas Kruse Hansen, Jeppe Sturis
  • Patent number: 9920107
    Abstract: The present invention refers to a method of purification of HMG (human menopausal gonadotropin) by multimodal chromatography in order to obtain HMG-UP (human menopausal gonadotropin with ultra-purity grade) composition.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: March 20, 2018
    Assignees: INSTITUTO MASSONE S.A., RAUL ENRIQUE MASSONE
    Inventors: Liliana Balanián, Mariana Cancela, Claudio Wolfenson, José Groisman
  • Patent number: 9920108
    Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 20, 2018
    Assignee: BRISTOl-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
  • Patent number: 9920109
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing and purifying such molecules.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: March 20, 2018
    Assignee: Inhibrx LP
    Inventors: Brendan Eckelman, John Timmer, Quinn Deveraux
  • Patent number: 9920110
    Abstract: In some embodiments, the invention relates to methods for creating a monoclonal antibody that specifically binds to antigen. The method may start from a polyclonal population of antibodies such as a non-specific polyclonal population or a polyclonal population of antibodies that specifically bind to the antigen. The method includes obtaining nucleic acid molecules encoding heavy and light immunoglobulin chains (or variable regions thereof) of multiple immunoglobulins from an animal; obtaining mass spectra information of peptide fragments of a population of polyclonal immunoglobulins that specifically bind to an antigen of choice; comparing and/or correlating the mass spectra information of the peptide fragments of the polyclonal immunoglobulins with predicted mass spectra information of predicted amino acid sequences encoded by the nucleic acid molecules, and then assembling the heavy and light chains to create an antibody (or variable region thereof) that specifically binds to the antigen.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: March 20, 2018
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Roberto Polakiewicz, Wan Cheung Cheung, John Edward Rush, II, Sean Andre Beausoleil
  • Patent number: 9920111
    Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: March 20, 2018
    Assignees: Theraclone Sciences, Inc., International Aids Vaccine Initiative, The Scripps Research Institute
    Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
  • Patent number: 9920112
    Abstract: The present invention relates to modified immunoglobulin-binding proteins, e.g., Staphylococcus protein A, having improved binding specificity for immunoglobulins and methods of making and using the same.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: March 20, 2018
    Assignee: EMD Millipore Corporation
    Inventor: Shari Spector
  • Patent number: 9920113
    Abstract: Methods and reagents for ameliorating biofilm formation on a surface of an indwelling or implanted device in a patient resulting in decreased virulence of microorganisms such as Candida species and/or Staphylococcus species.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 20, 2018
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI, YALE UNIVERSITY
    Inventors: Margaret K. Hostetter, Long Lu, Julianne Vernadette Green, Alexey Porollo, Kris I. Orsborn, Khoon Ghee Queenie Tan, Kenneth Greis, David Andes
  • Patent number: 9920114
    Abstract: Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: March 20, 2018
    Assignee: AMGEN INC.
    Inventors: Bruce D. Mason, Jifeng Zhang, Richard L. Remmele, Jr.
  • Patent number: 9920115
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: March 20, 2018
    Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
  • Patent number: 9920116
    Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: March 20, 2018
    Assignee: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
  • Patent number: 9920117
    Abstract: Two types of antibodies (35-1 antibody and 292 antibody) capable of binding to phenylalanine at position 115, isoleucine at position 117, glycine at position 140, glutamic acid at position 141, and arginine at position 142 of a human HB-EGF protein were successfully obtained. Then, it was also found that these antibodies had an activity of suppressing cleavage of the human HB-EGF protein, and an activity of suppressing EGFR phosphorylation that would occur when the human HB-EGF bound to the EGFR. Further, determined were amino acid sequences of light chain and heavy chain variable regions of these antibodies and sequences of CDRs of each of the variable regions.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: March 20, 2018
    Assignee: MEDICAL & BIOLOGICAL LABORATIVES CO., LTD.
    Inventors: Kenichiro Ono, Junichi Akatsuka
  • Patent number: 9920118
    Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: March 20, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Wenyan Shen, Darrin Anthony Lindhout, Raj Haldankar, Hugo Matern
  • Patent number: 9920119
    Abstract: New chimeric molecules involving in their structure, a combination of the extracellular domain (EC) of the FasL protein and a domain enabling oligomerisation of this Fas Ligand (FasL) EC domain, such as the Ig-like (so-called Ig in the following pages) domain of the gp190 receptor for the Leukemia Inhibitory Factor (LIF), or involving in their structure variants of the domains. Also, compositions including the chimeric molecule defined herein and the use of these chimeric molecules especially to trigger cytotoxic activity toward cells sensitive to FasL.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: March 20, 2018
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Luc Taupin, Sophie Daburon, Jean-Francois Moreau, Myriam Capone
  • Patent number: 9920120
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: March 20, 2018
    Assignee: Genentech, Inc.
    Inventors: X. Christopher Yu, Susan C. Fisher, Ailen M. Sanchez, Martin Vanderlaan
  • Patent number: 9920121
    Abstract: The present disclosure provides a human antibody or antigen binding fragment thereof or an antibody construct comprising a human binding domain or antigen binding fragment thereof capable of binding to human CDH19 on the surface of a target cell. The disclosure relates to a nucleic acid sequence encoding the antibody or antigen binding fragment thereof contained in the antibody construct, a vector comprising the nucleic acid sequence and a host cell transformed or transfected with the vector. Furthermore, the disclosure relates to a process for the production of the antibody construct of the disclosure, a medical use or a method of treatment using the antibody construct and a kit comprising the antibody or antigen binding fragment thereof or the antibody construct.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 20, 2018
    Assignee: AMGEN INC.
    Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan
  • Patent number: 9920122
    Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: March 20, 2018
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventor: Timo Kars van den Berg
  • Patent number: 9920123
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: March 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • Patent number: 9920124
    Abstract: The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Alan Hunter, Thomas Linke, Timothy Pabst, Michaela Wendeler, Xiangyang Wang, Christopher Thompson, Guoling Xi, Andrew Fulton
  • Patent number: 9920125
    Abstract: Methods for reduction of aggregate levels in antibody and other protein preparations comprising the steps of treatment with an organic multivalent cation (e.g., ethacridine, chlorhexidine, or polyethylenimine) and treatment with a composition having a combination of surfaces bearing electronegative chemical moieties and surfaces bearing electropositive chemical moieties.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: March 20, 2018
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Peter Gagnon
  • Patent number: 9920127
    Abstract: Disclosed herein are methods of treating pain using RANK/RANKL antagonists.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: March 20, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9920128
    Abstract: A method for synthesizing an antiserum for rapid-turnaround therapies includes collecting antibody-secreting cells from a test subject, wherein the test subject has been exposed to a target biological agent and has produced an antibody response; selecting a subset of the antibody-secreting cells, the subset of the antibody-secreting cells producing antibodies that neutralize the target biological agent; generating variable-region-coding DNA sequences from the antibodies that neutralize the target biological agent; tagging amplicons of the variable-region-coding DNA sequences with unique nucleic acid identifiers to associate the variable-region-coding DNA sequences derived from individual ones of the subset of the antibody-secreting cells; analyzing antibody-type distribution in a natural immune response; synthesizing antibodies from the variable-region-coding DNA sequences to form synthetic antibodies; and mixing the synthetic antibodies in a proportion equal to the antibody-type distribution in the natural i
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: March 20, 2018
    Assignee: The Johns Hopkins University
    Inventors: Jeffrey S. Lin, Andrew B. Feldman, Jared D. Evans, Joshua T. Wolfe, David Weitz, John Heyman, Andrew S. Pekosz
  • Patent number: 9920129
    Abstract: Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: March 20, 2018
    Assignees: THE UNIVERSITY OF TOKYO, CHUGAI SEIY AKU KABUSHIKI KAISHA
    Inventors: Hiroyuki Aburatani, Shumpei Ishikawa, Shigeto Kawai
  • Patent number: 9920130
    Abstract: A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 20, 2018
    Assignee: KATINGER GMBH
    Inventors: Hermann Katinger, Renate Kunert, Thomas Sterovsky, Thomas Hemetsberger
  • Patent number: 9920131
    Abstract: Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 20, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Jeffrey David Kearns, Beni B. Wolf
  • Patent number: 9920132
    Abstract: The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: March 20, 2018
    Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, DRK Blutspendedienst Baden-Wurttemberg-Hessen gGmbH
    Inventors: Winfried Wels, Kurt Schonfeld, Torsten Tonn, Manuel Grez, Congcong Zhang
  • Patent number: 9920133
    Abstract: Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: March 20, 2018
    Assignees: NATIONAL CANCER CENTER, The University of Tokyo, RIKEN, NanoCarrier Co., Ltd.
    Inventors: Yasuhiro Matsumura, Masahiro Yasunaga, Yoshikatsu Koga, Yoshiyuki Yamamoto, Ryuta Sato, Ryo Tsumura, Kazunori Kataoka, Nobuhiro Nishiyama, Yutaka Miura, Shino Manabe, Yasuki Kato
  • Patent number: 9920134
    Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: March 20, 2018
    Assignee: AMGEN INC.
    Inventors: Simon Mark Jackson, Nigel Pelham Clinton Walker, Derek Evan Piper, Bei Shan, Wenyan Shen, Joyce Chi Yee Chan, Chadwick Terrence King, Randal Robert Ketchem, Christopher Mehlin, Teresa Arazas Carabeo, Qiong Cao
  • Patent number: 9920135
    Abstract: It is intended to provide an anti-human CD26 antibody which permits analysis, etc., of the expression of CD26 in cancer tissues, immune tissues, or the like, for example, in order to select a patient applicable to treatment or to monitor therapeutic effects, and can also be used in immunostaining. The present invention relates to an anti-human CD26 monoclonal antibody or an antigen-binding fragment thereof, binding to an epitope which is recognized by a monoclonal antibody produced by a hybridoma deposited under Accession No. NITE BP-01642, a hybridoma deposited under Accession No. NITE BP-01643, or a hybridoma deposited under Accession No. NITE BP-01644.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 20, 2018
    Assignee: JUNTENDO EDUCATIONAL FOUNDATION
    Inventors: Chikao Morimoto, Ryo Hatano, Taketo Yamada, Kei Ohnuma
  • Patent number: 9920136
    Abstract: Methods, compositions and kits are disclosed directed at posaconazole fragments, immunogens, signal generating moieties, antibodies that bind posaconazole and immunoassays for detection of posaconazole.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: March 20, 2018
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Valdez, Soon J. Oh, Byung Sook Moon
  • Patent number: 9920137
    Abstract: A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.
    Type: Grant
    Filed: July 5, 2015
    Date of Patent: March 20, 2018
    Assignee: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Dale Howard Hreczuk-Hirst, Sanjay Jain, Peter Laing, Gregory Gregoriadis, Ioannis Papaioannou
  • Patent number: 9920138
    Abstract: The present invention relates to alternan-carboxylic acid esters, to processes for the preparation of alternan-carboxylic acid esters, and to compositions comprising alternan-carboxylic acid esters and to the use of alternan-carboxylic acid esters. The invention relates to alternan-carboxylic acid esters which are emulsifiers.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: March 20, 2018
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Claus Frohberg, Waltraud Vorwerg, Sylvia Radosta
  • Patent number: 9920139
    Abstract: Provided is a suspension comprising liquid droplets dispersed in an aqueous medium, wherein said droplets comprise (a) one or more water-insoluble compounds, and (b) a vinyl polyelectrolyte (PED) having a polarity, and wherein said aqueous medium comprises a polyelectrolyte (PEW) having a polarity that is opposite to the polarity of said polyelectrolyte (PED). Also provided are a method of making such a suspension and a method using such a suspension in a process of suspension polymerization.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: March 20, 2018
    Assignees: Rohm and Haas Company, Dow Global Technologies LLC
    Inventors: Matthew D. Reichert, Alfred K. Schultz, Andrew M. Savo, Steven Rosenberg, Ralph C. Even, Lester H. Mcintosh, III, Robert Johnson, John David Finch, Decai Yu
  • Patent number: 9920140
    Abstract: The invention relates to aqueous, cationically stabilized primary dispersions comprising dispersed polymer particles having a Z-average particle diameter of 5 to 500 nm and which are obtainable by emulsion polymerization of at least one olefinically unsaturated monomer (A). The emulsion polymerization takes place in the presence of one or more emulsifiers (EQ) having the following general formula: R1—N?(R2)(R3)(R4)X?, where R1 is a moiety with 15 to 40 carbon atoms which contains at least one aromatic group and at least one aliphatic group, and which contains at least one functional group selected from hydroxyl groups, thiol groups, and primary or secondary amino groups, and/or has at least one carbon-carbon multiple bond, R2, R3, and R4, independently of one another, are the same or different aliphatic moieties containing 1 to 14 carbon atoms, and X stands for the acid anion of an organic or inorganic acid.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 20, 2018
    Inventors: Konstantinos Markou, Andreas Niegemeier, Sabine Holtschulte
  • Patent number: 9920141
    Abstract: A process for manufacturing a dispersions of a vinylidene fluoride (VDF) thermoplastic polymer [polymer (F)], said process comprising polymerizing VDF in an aqueous phase comprising: at least one surfactant selected from the group consisting of non-fluorinated surfactants [surfactant (HS)] and fluorinated surfactants having a molecular weight of less than 400 [surfactant (FS)]; and at least one functional (per)fluoropolyether (functional PFPE) comprising at least one (per)fluoropolyoxyalkylene chain [chain (R?F)] and at least one functional group, said functional PFPE having a number average molecular weight of at least 1000 and a solubility in water of less than 1% by weight at 25° C., wherein said functional PFPE is present in the aqueous phase in an amount of 0.001 to 0.3 g/l.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: March 20, 2018
    Assignee: SOLVAY SPECIALTY POLYMERS ITALY S.P.A.
    Inventors: Fabrizio Spada, Bradley Lane Kent
  • Patent number: 9920142
    Abstract: A (meth)acrylic resin composition is obtained by a method that comprises: preparing a liquid starting material (A) comprising methyl methacrylate, an acrylic acid alkyl ester and a chain transfer agent, having a mass ratio of the acrylic acid alkyl ester to the methyl methacrylate of 0/100 to 20/80, and having a dissolved oxygen concentration of not more than 50 ppm, preparing a liquid starting material (B) comprising a radical polymerization initiator, a polymerization inhibitor and methyl methacrylate, and having been maintained at a temperature of not more than 10° C. in the presence of oxygen, continuously feeding the liquid starting material (A) and the liquid starting material (B) into a tank reactor, allowing bulk polymerization to proceed in the tank reactor at a polymerization conversion ratio of 40 to 70% by mass to give a reaction product, and continuously discharging the reaction product from the tank reactor.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: March 20, 2018
    Assignee: KURARAY CO., LTD.
    Inventors: Yasuhito Kitade, Hiroshi Ozawa, Shouji Tanaka
  • Patent number: 9920143
    Abstract: A fluorine-containing highly branched polymer obtained by polymerizing a polyfunctional monomer A that has two or more radically polymerizable double bonds and all or a portion of which has a bisphenol structure, a monomer B having a fluoroalkyl group and at least one radically polymerizable double bond, within a molecule, and a monomer C having at least one ring-opening polymerizable group selected from the group including an epoxy group and an oxetanyl group, and having at least one radically polymerizable double bond, within a molecule, under the presence of a polymerization initiator D with an amount of 5% by mole to 200% by mole to the number of moles of the polyfunctional monomer A; an epoxy resin composition including the polymer; and an epoxy resin cured product obtained from the resin composition.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: March 20, 2018
    Assignee: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Tomoko Misaki, Motonobu Matsuyama, Masayuki Haraguchi, Masaaki Ozawa
  • Patent number: 9920144
    Abstract: The present disclosure relates to a porous solid adduct comprising magnesium chloride and ethanol, characterized by a relationship between the content of alcohol, average pore radius and amount of porosity deriving from pores with radii of 100-1000 nm, and catalyst components produced therefrom that are capable of producing polyolefins with increased porosity.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: March 20, 2018
    Assignee: Basell Poliolefine Italia S.r.l.
    Inventors: Arrigo Arletti, Lucia Caiazzo, Gianni Collina, Daniele Evangelisti, Ofelia Fusco, Benedetta Gaddi
  • Patent number: 9920145
    Abstract: The present invention relates to tackifier compounds and methods of using the same. In various embodiments, the present invention provides a tackifier compound including independently substituted or unsubstituted fused rings A and B each independently chosen from (C5-C10)cycloalkyl and (C2-C10)heterocyclyl. Fused ring A is substituted with (R1)1-8 and fused ring B is substituted with —(OC(O)R?C(O)R2)1-8. At each occurrence R? is independently chosen from (C2-C10)alkanylene, (C2-C10)alkenylene, (C2-C10)alkynylene, C5-C20(arylene), and (C1-C20)heteroarylene, wherein R? is unsubstituted or substituted. At each occurrence R1 is independently selected from —OH, —OR3, and —OC(O)R?C(O)R2. At each occurrence R2 is independently chosen from —OH, —OR3, —NH2, —NHR3, and —NR32. At each occurrence R3 is independently chosen from (C1-C10)alkanyl, (C2-C10)alkenyl, (C2-C10)alkynyl, C5-C20(aryl), and (C1-C20)heteroaryl, wherein R3 is unsubstituted or substituted.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: March 20, 2018
    Assignee: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Jason Shih-Hao Chen, Michael Richard Kessler, Michael Dennis Zenner
  • Patent number: 9920146
    Abstract: Provided is a method of treatment of an alcoholic beverage, particularly beer or wine, for removing ingredient(s) causing undesirable sulfury and/or fatty flavor(s), by contacting the beverage with a composition having a polymer-hydrogen peroxide complex, wherein the polymer is derived from at least one N-vinyl lactam monomer, and wherein the hydrogen peroxide is present in an amount from about 1% by weight to about 50% by weight of the complex. Provided further is a method of treatment of an alcoholic beverage to remove at least (a) at least one ingredient causing at least one undesirable sulfury and/or fatty flavor, and (b) at least one ingredient causing colloidal haze, including contacting the beverage with a composition described herein. Provided furthermore is an alcoholic beverage obtained by the method(s) of treatment described herein.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: March 20, 2018
    Assignee: ISP Investments LLC
    Inventors: Krishnamurthy Nacharaju, Giovanni Nicola Onnembo, Mustafa Rehmanji, Andrew Mola, Bala Balasanmugam, Joycelyn Yapchulay
  • Patent number: 9920147
    Abstract: The present technology relates to a polymeric material including a plurality of polymer subunits and an active cross-linker, wherein the active cross-linker is covalently linked to the plurality of polymer subunits. The active cross-linker offers a key building block for constructing novel molecular architecture in chemomechanical soft materials and illustrates a new approach to tailor material properties.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: March 20, 2018
    Assignee: Brandeis University
    Inventors: Ye Zhang, Bing Xu
  • Patent number: 9920148
    Abstract: A vehicle part cover including a methacrylic-based resin (I) having a weight average molecular weight measured by gel permeation chromatography (GPC) of 65,000 to 300,000, the methacrylic-based resin (I) comprising: 50 to 97% by mass of a methacrylate monomer unit (A); 3 to 30% by mass of a structural unit (B) having a ring structure in its main chain, and being at least one selected from the group consisting of a maleimide-based structural unit, a glutaric anhydride structural unit, a glutarimide-based structural unit, and a lactone ring structural unit; and 0 to 20% by mass of another vinyl monomer unit (C) that is copolymerizable with a methacrylate monomer.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: March 20, 2018
    Assignee: Asahi Kasei Chemicals Corporation
    Inventor: Fumiki Murakami
  • Patent number: 9920149
    Abstract: Polymers are functionalized at chain ends thereof with silane-containing carboxyl groups of the formula (I) where R1 and R2 are the same or different and are each an H, alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, alkaryl, alkaryloxy, aralkyl or aralkoxy radical; R3 and R4 are the same or different and are each an H, alkyl, cycloalkyl, aryl, alkaryl or aralkyl radical; and A is a divalent organic radical.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: March 20, 2018
    Assignee: ARLANXEO Deutschland GmbH
    Inventors: Norbert Steinhauser, Thomas Gross
  • Patent number: 9920150
    Abstract: A process is described for the production of phosphorus-containing organic polymers through reaction of dialkyl phosphites with organic polymers comprising carbon-carbon double bonds in the presence of organic compounds that form free radicals under the reaction conditions, with covalent linkage of the phosphorus atom of the dialkyl phosphite to a carbon atom of the organic polymer.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: March 20, 2018
    Assignee: BASF SE
    Inventors: Alexander Koenig, Konrad Knoll